Market Spotlight: Irritable Bowel Syndrome (IBS)
Market Spotlight: Irritable Bowel Syndrome (IBS)
$1,318.00
This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were approximately 714.1 million prevalent cases of irritable bowel syndrome (IBS) in those aged 15 years and over worldwide, and forecasts that number to increase to 785.7 million prevalent cases by 2028.
- The approved drugs in the IBS space target chloride channel 2, calcium channel, sodium-hydrogen exchanger 3, serotonin 5- HT3 receptor, guanylyl cyclase c receptor, opioid receptors, gram-negative bacteria, RNA polymerase, and serotonin 5-HT4 receptor. These drugs are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for IBS are in Phase II.
- Therapies in development for IBS focus on a wide variety of targets. All of the pipeline drugs are administered via the oral route. High-impact upcoming events for drugs in the IBS space comprise topline Phase II trial results for ORP-101 and Aemcolo, and topline Phase IIa trial results for vibegron.
- The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 17.1%, and the average probability a drug advances from Phase III is 65.7%. Drugs, on average, take 10.0 years from Phase I to approval, compared to 9.8 years in the overall gastroenterology (non inflammatory bowel disease) space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for IBS have been in the early and midphases of development, with 65% of trials in Phase I–II, and only 35% in Phase III–IV.
- The US has a substantial lead in the number of IBS clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the IBS space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for IBS, with 52 trials.
- AbbVie leads industry sponsors with the highest overall number of clinical trials for IBS, followed by GlaxoSmithKline.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Laxatives
9 Antidiarrheal drugs
9 Antispasmodics
9 Antidepressants
9 Serotonin receptor agonists
10 Chloride channel activators
10 Guanylyl cyclase C agonists
10 Antibiotics
10 Opioid receptors
10 Probiotics
12 EPIDEMIOLOGY
18 MARKETED DRUGS
21 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 Vibegron for IBS (November 24, 2020)
28 Blautix for IBS (October 7, 2020)
29 SYN-010 for IBS (October 2, 2020)
30 Zelnorm for IBS (July 8, 2019)
31 Multiple Drugs for IBS (June 25, 2019)
32 Linzess for IBS (June 18, 2019)
34 IB-Stim for IBS (June 7, 2019)
36 KEY UPCOMING EVENTS
37 KEY REGULATORY EVENTS
37 Gastroenterologist Group Advises Against Probiotics For Most Digestive Conditions
38 PROBABILITY OF SUCCESS
39 LICENSING AND ASSET ACQUISITION DEALS
39 Ireland’s Kerry Expands Probiotics Offering
39 Nestle Acquires IM HealthScience, Expands Medical Food Lineup In Latest US Consumer Move
39 Sanofi Tapping AI To Help Consumers Manage IBS
39 Sanofi Personalizing IBS Treatment With Digital Therapy
41 REVENUE OPPORTUNITY
42 CLINICAL TRIAL LANDSCAPE
43 Sponsors by status
44 Sponsors by phase
46 BIBLIOGRAPHY
47 Prescription information
48 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of IBS, 2019–28
17 Figure 2: Prevalent cases of IBS, by age group, 2019
21 Figure 3: Overview of pipeline drugs for IBS in the US
22 Figure 4: Pipeline drugs for IBS, by company
22 Figure 5: Pipeline drugs for IBS, by drug type
22 Figure 6: Pipeline drugs for IBS, by classification
28 Figure 7: Vibegron for IBS (November 24, 2020): Phase IIa – URO-901-2001
29 Figure 8: Blautix for IBS (October 7, 2020): Phase II – BHT-II-002
34 Figure 9: Linzess for IBS (June 18, 2019): Phase IIIb – IBS-C Abdominal Symptoms
36 Figure 10: Key upcoming events in IBS
38 Figure 11: Probability of success in the gastroenterology (non inflammatory bowel disease)-other pipeline
42 Figure 12: Clinical trials in IBS
42 Figure 13: Top 10 drugs for clinical trials in IBS
43 Figure 14: Top 10 companies for clinical trials in IBS
43 Figure 15: Trial locations in IBS
44 Figure 16: IBS trials status
45 Figure 17: IBS trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of IBS, 2019–28
15 Table 2: Prevalent cases of IBS, by gender, 2019
16 Table 3: Prevalence of IBS, by gender, 2019
19 Table 4: Marketed drugs for IBS
24 Table 5: Pipeline drugs for IBS in the US
27 Table 6: Vibegron for IBS (November 24, 2020)
28 Table 7: Blautix for IBS (October 7, 2020)
30 Table 8: SYN-010 for IBS (October 2, 2020)
31 Table 9: Zelnorm for IBS (July 8, 2019)
32 Table 10: Multiple Drugs for IBS (June 25, 2019)
33 Table 11: Linzess for IBS (June 18, 2019)
34 Table 12: IB-Stim for IBS (June 7, 2019)
41 Table 13: Historical global sales, by drug ($m), 2015–19
41 Table 14: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Insomnia 
Sign up to the